Monoclonal antibody targeting staphylococcus aureus surface protein A (SasA) protect against staphylococcus aureus sepsis and peritonitis in mice

PLoS ONE

Volumn 11, Issue 2, 2016, Pages

  Yang, Yilong ^a   Qian, Mengying ^a   Yi, Shaoqiong ^a   Liu, Shuling ^a   Li, Bing ^b   Yu, Rui ^a   Guo, Qiang ^a   Zhang, Xiaopeng ^a   Yu, Changming ^a   Li, Jianmin ^a   Xu, Junjie ^a   Chen, Wei ^a  

^a BEIJING INSTITUTE OF BIOTECHNOLOGY   (China)

^b 306 HOSPITAL OF PLA   (China)

Author keywords

[No Author keywords available]

Indexed keywords

OCRELIZUMAB; STAPHYLOCOCCUS PROTEIN A; ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; MONOCLONAL ANTIBODY; PROTEIN BINDING;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL CLEARANCE; BACTERIAL PERITONITIS; BACTERICIDAL ACTIVITY; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG TARGETING; EX VIVO STUDY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MOUSE; NEUTROPHIL; NONHUMAN; PASSIVE IMMUNIZATION; PHAGOCYTOSIS; PROTECTION; SINGLE DRUG DOSE; STAPHYLOCOCCAL BACTEREMIA; SURVIVAL RATE; THROMBOCYTE; WILD TYPE; ANIMAL; ANTAGONISTS AND INHIBITORS; DISEASE MODEL; DNA SEQUENCE; DRUG EFFECTS; GENETICS; IMMUNOLOGY; METABOLISM; MICROBIOLOGY; MORTALITY; PERITONITIS; SEPSIS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTIBODIES, MONOCLONAL; BACTERIAL PROTEINS; BLOOD PLATELETS; DISEASE MODELS, ANIMAL; FEMALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICE; PERITONITIS; PHAGOCYTOSIS; PROTEIN BINDING; SEPSIS; SEQUENCE ANALYSIS, DNA; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 84960540493     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0149460     Document Type: Article

References (38)

1. Lowy FD. Staphylococcus aureus infections. N Engl J Med. 1998; 339(8):520-32. PMID: 9709046
2. Klevens RM, Edwards JR, Gaynes RP. The impact of antimicrobial-resistant, health care-associated infections on mortality in the United States. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2008; 47(7):927-30.
3. Moran GJ, Krishnadasan A, Gorwitz RJ, Fosheim GE, McDougal LK, Carey RB, et al. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med. 2006; 355 (7):666-74. PMID: 16914702
4. Thwaites GE, Edgeworth JD, Gkrania-Klotsas E, Kirby A, Tilley R, Torok ME, et al. Clinical management of Staphylococcus aureus bacteraemia. Lancet Infect Dis. 2011; 11(3):208-22. doi: 10.1016/S1473-3099(10)70285-1 PMID: 21371655
5. Verkaik NJ, van Wamel WJ, van Belkum A. Immunotherapeutic approaches against Staphylococcus aureus. Immunotherapy. 2011; 3(9):1063-73. doi: 10.2217/imt.11.84 PMID: 21913829
6. Proctor RA. Challenges for a universal Staphylococcus aureus vaccine. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2012; 54(1537-6591 (Electronic)): 1179-86.
7. Ragle BE, Bubeck Wardenburg J. Anti-alpha-hemolysin monoclonal antibodies mediate protection against Staphylococcus aureus pneumonia. Infection and immunity. 2009; 77(7):2712-8. doi: 10.1128/IAI.00115-09 PMID: 19380475
8. Rauch S, DeDent AC, Kim HK, Bubeck Wardenburg J, Missiakas DM, Schneewind O. Abscess formation and alpha-hemolysin induced toxicity in a mouse model of Staphylococcus aureus peritoneal infection. Infection and immunity. 2012; 80(10):3721-32. doi: 10.1128/IAI.00442-12 PMID: 22802349
9. Foletti D, Strop P, Shaughnessy L, Hasa-Moreno A, Casas MG, Russell M, et al. Mechanism of action and in vivo efficacy of a human-derived antibody against Staphylococcus aureus alpha-hemolysin. Journal of molecular biology. 2013; 425(10):1641-54. doi: 10.1016/j.jmb.2013.02.008 PMID: 23416200
10. Hilliard JJ, Datta V, Tkaczyk C, Hamilton M, Sadowska A, Jones-Nelson O, et al. Anti-alpha-toxin monoclonal antibody and antibiotic combination therapy improves disease outcome and accelerates healing in a Staphylococcus aureus dermonecrosis model. Antimicrobial agents and chemotherapy. 2015; 59(1):299-309. doi: 10.1128/AAC.03918-14 PMID: 25348518
11. Hall AE, Domanski PJ, Patel PR, Vernachio JH, Syribeys PJ, Gorovits EL, et al. Characterization of a protective monoclonal antibody recognizing Staphylococcus aureus MSCRAMM protein clumping factor A. Infection and immunity. 2003; 71(12):6864-70. PMID: 14638774
12. Ebert T, Smith S, Pancari G, Clark D, Hampton R, Secore S, et al. A fully human monoclonal antibody to Staphylococcus aureus iron regulated surface determinant B (IsdB) with functional activity in vitro and in vivo. Human antibodies. 2010; 19(4):113-28. doi: 10.3233/HAB-2010-0235 PMID: 21178283
13. Provenza G, Provenzano M, Visai L, Burke FM, Geoghegan JA, Stravalaci M, et al. Functional analysis of a murine monoclonal antibody against the repetitive region of the fibronectin-binding adhesins fibronectin-binding protein A and fibronectin-binding protein B from Staphylococcus aureus. FEBS J. 2010; 277(21):4490-505. doi: 10.1111/j.1742-4658.2010.07835.x PMID: 20875085
14. Lorenz U, Lorenz B, Schmitter T, Streker K, Erck C, Wehland J, et al. Functional antibodies targeting IsaA of Staphylococcus aureus augment host immune response and open new perspectives for antibacterial therapy. Antimicrobial agents and chemotherapy. 2011; 55(1):165-73. doi: 10.1128/AAC. 01144-10 PMID: 20956605
15. Kim HK, Emolo C, DeDent AC, Falugi F, Missiakas DM, Schneewind O. Protein A-specific monoclonal antibodies and prevention of Staphylococcus aureus disease in mice. Infection and immunity. 2012; 80 (10):3460-70. doi: 10.1128/IAI.00230-12 PMID: 22825452
16. Pancari G, Fan H, Smith S, Joshi A, Haimbach R, Clark D, et al. Characterization of the mechanism of protection mediated by CS-D7, a monoclonal antibody to Staphylococcus aureus iron regulated surface determinant B (IsdB). Frontiers in cellular and infection microbiology 2012.
17. van den Berg S, Bonarius HP, van Kessel KP, Elsinga GS, Kooi N, Westra H, et al. A human monoclonal antibody targeting the conserved staphylococcal antigen IsaA protects mice against Staphylococcus aureus bacteremia. International journal of medical microbiology: IJMM. 2015; 305(1):55-64. PMID: 25466204
18. Weisman LE, Thackray HM, Garcia-Prats JA, Nesin M, Schneider JH, Fretz J, et al. Phase 1/2 doubleblind, placebo-controlled, dose escalation, safety, and pharmacokinetic study of pagibaximab (BSYXA110), an antistaphylococcal monoclonal antibody for the prevention of staphylococcal bloodstream infections, in very-low-birth-weight neonates. Antimicrobial agents and chemotherapy. 2009; 53 (7):2879-86. doi: 10.1128/AAC.01565-08 PMID: 19380597
19. Park J, Jagasia R, Kaufmann GF, Mathison JC, Ruiz DI, Moss JA, et al. Infection control by antibody disruption of bacterial quorum sensing signaling. Chemistry & biology. 2007; 14(10):1119-27.
20. Siboo IR, Chambers HF, Sullam PM. Role of SraP, a Serine-Rich Surface Protein of Staphylococcus aureus, in binding to human platelets. Infection and immunity. 2005; 73(4):2273-80. PMID: 15784571
21. Lizcano A, Sanchez CJ, Orihuela CJ. A role for glycosylated serine-rich repeat proteins in gram-positive bacterial pathogenesis. Mol Oral Microbiol. 2012; 27(4):257-69. doi: 10.1111/j.2041-1014.2012.00653. x PMID: 22759311
22. Yi SQ, Zhang XY, Yang YL, Yang Y, Liu SL, Fu L, et al. Immunity induced by Staphylococcus aureus surface protein A was protective against lethal challenge of Staphylococcus aureus in BALB/c mice. Microbiol Immunol. 2012; 56(6):406-10. doi: 10.1111/j.1348-0421.2012.00451.x PMID: 22420921
23. Roche FM, Massey R, Peacock SJ, Day NP, Visai L, Speziale P, et al. Characterization of novel LPXTG-containing proteins of Staphylococcus aureus identified from genome sequences. Microbiology (Reading, England). 2003; 149(Pt 3):643-54.
24. Diep BA, Gill SR, Chang RF, Phan TH, Chen JH, Davidson MG, et al. Complete genome sequence of USA300, an epidemic clone of community-acquired meticillin-resistant Staphylococcus aureus. Lancet. 2006; 367(9512):731-9. PMID: 16517273
25. Xiao M, Wang H, Zhao Y, Mao LL, Brown M, Yu YS, et al. National surveillance of methicillin-resistant Staphylococcus aureus in China highlights a still-evolving epidemiology with 15 novel emerging multilocus sequence types. Journal of clinical microbiology. 2013; 51(11):3638-44. doi: 10.1128/JCM.01375-13 PMID: 23985906
26. KÖHLER G, MILSTEIN C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256:495-7. PMID: 1172191
27. Park S, Gerber S, Lee JC. Antibodies to Staphylococcus aureus serotype 8 capsular polysaccharide react with and protect against serotype 5 and 8 isolates. Infection and immunity. 2014; 82(12):5049-55. doi: 10.1128/IAI.02373-14 PMID: 25245803
28. Kearse M, Moir R, Wilson A, Stones-Havas S, Cheung M, Sturrock S, et al. Geneious Basic: an integrated and extendable desktop software platform for the organization and analysis of sequence data. Bioinformatics (Oxford, England). 2012; 28(12):1647-9.
29. Shivshankar P, Sanchez C, Rose LF, Orihuela CJ. The Streptococcus pneumoniae adhesin PsrP binds to Keratin 10 on lung cells. Mol Microbiol. 2009; 73(4):663-79. doi: 10.1111/j.1365-2958.2009. 06796.x PMID: 19627498
30. Govindarajulu S, Hawley CM, McDonald SP, Brown FG, Rosman JB, Wiggins KJ, et al. Staphylococcus aureus peritonitis in Australian peritoneal dialysis patients: predictors, treatment, and outcomes in 503 cases. Peritoneal dialysis international: journal of the International Society for Peritoneal Dialysis. 2010; 30(3):311-9.
31. Stranger-Jones YK, Bae T, Schneewind O. Vaccine assembly from surface proteins of Staphylococcus aureus. Proceedings of the National Academy of Sciences of the United States of America. 2006; 103 (45):16942-7. PMID: 17075065
32. Casadevall A, Dadachova E, Pirofski LA. Passive antibody therapy for infectious diseases. Nature reviews Microbiology. 2004; 2(9):695-703. PMID: 15372080
33. Saylor C, Dadachova E, Casadevall A. Monoclonal antibody-based therapies for microbial diseases. Vaccine. 2009; 27 Suppl 6:G38-46. doi: 10.1016/j.vaccine.2009.09.105 PMID: 20006139
34. Yang YH, Jiang YL, Zhang J, Wang L, Bai XH, Zhang SJ, et al. Structural insights into SraP-mediated Staphylococcus aureus adhesion to host cells. PLoS pathogens. 2014; 10(6):e1004169. doi: 10.1371/journal.ppat.1004169 PMID: 24901708
35. Zacharioudakis IM, Zervou FN, Ziakas PD, Mylonakis E. Meta-analysis of methicillin-resistant Staphylococcus aureus colonization and risk of infection in dialysis patients. Journal of the American Society of Nephrology: JASN. 2014; 25(9):2131-41. doi: 10.1681/ASN.2013091028 PMID: 24652802
36. Nguyen DB, Lessa FC, Belflower R, Mu Y, Wise M, Nadle J, et al. Invasive methicillin-resistant Staphylococcus aureus infections among patients on chronic dialysis in the United States, 2005-2011. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2013; 57 (10):1393-400.
37. Broughan J, Anderson R, Anderson AS. Strategies for and advances in the development of Staphylococcus aureus prophylactic vaccines. Expert review of vaccines. 2011; 10(5):695-708. doi: 10.1586/erv.11.54 PMID: 21604989
38. Bagnoli F, Bertholet S, Grandi G. Inferring reasons for the failure of Staphylococcus aureus vaccines in clinical trials. Frontiers in cellular and infection microbiology. 2012; 2:16. doi: 10.3389/fcimb.2012. 00016 PMID: 22919608